Evidence map›Paper›PMID 37106995›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors.

Nakita Reddy, Letisha Girdhari, Mbongeni Shungube, Arnoldus C Gouws, Byron K Peters, Kamal K Rajbongshi, Sooraj Baijnath, Sipho Mdanda, Thandokuhle Ntombela, Thilona Arumugam and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Development andRSC advances · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nakita ReddyCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.
Letisha GirdhariCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0001-5841-2735
Mbongeni ShungubeCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.
Arnoldus C GouwsCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0002-9848-719X
Byron K PetersCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.
Kamal K RajbongshiCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0003-0128-663X
Sooraj BaijnathCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0001-7860-1779
Sipho MdandaCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0003-0146-0538
Thandokuhle NtombelaCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.
Thilona ArumugamSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.
Linda A BesterSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.ORCID 0000-0001-5726-681X
Sanil D SinghDepartment of Pharmaceutical Sciences, University of KwaZulu-Natal, Westville Campus, Durban 3629, South Africa.
Anil ChuturgoonSchool of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa.ORCID 0000-0003-4649-4133
Per I ArvidssonCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0002-9453-6812
Glenn E M MaguireCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.
Hendrik G KrugerCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0003-0606-2053
Thavendran GovenderDepartment of Chemistry, University of Zululand, Private Bag X1001, KwaDlangezwa 3886, South Africa.ORCID 0000-0003-2511-2503
Tricia NaickerCatalysis and Peptide Research Unit, University of KwaZulu-Natal, Durban 4001, South Africa.ORCID 0000-0002-7134-6258

Funding

National Research Foundation 120419, 137979, 145774, 105236, 105216, 105303South African Medical Research Council BRICS JAF 2021/033The Technology Innovation Agency of South Africa UKZN_17-18_1
6 · The paper itself

Abstract

Virulent Enterobacterale strains expressing serine and metallo-β-lactamases (MBL) genes have emerged responsible for conferring resistance to hard-to-treat infectious diseases. One strategy that exists is to develop β-lactamase inhibitors to counter this resistance. Currently, serine β-lactamase inhibitors (SBLIs) are in therapeutic use. However, an urgent global need for clinical metallo-β-lactamase inhibitors (MBLIs) has become dire. To address this problem, this study evaluated BP2, a novel beta-lactam-derived β-lactamase inhibitor, co-administered with meropenem. According to the antimicrobial susceptibility results, BP2 potentiates the synergistic activity of meropenem to a minimum inhibitory concentration (MIC) of ≤1 mg/L. In addition, BP2 is bactericidal over 24 h and safe to administer at the selected concentrations. Enzyme inhibition kinetics showed that BP2 had an apparent inhibitory constant (K

Indexed as

BP2Carbapenem resistant Enterobacteralescyclic amino acidic chelatormetallo-β-lactamasesmurine thigh infection model

Identifiers

PMID37106995
PMCPMC10135050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.